CCL2 and metabolic dysfunction-associated steatohepatitis: Treatment with a dual antagonist for CCR2 and CCR5, receptors for CCL2 and CCL5, significantly reduced macrophages and protected rats from liver injury in a diet induced NASH model (79) and has shown promising effects for NASH in phase II clinical trial (80).